ACQUISITION OF NON-CATALOGED MEDICINES GROUP A (INSULINS AND OTHERS) FIRST QUARTER - 2025 PROGRAMMING.- PHARMACY AND THERAPEUTICS COMMITTEE MINUTES 002 – 2025.

This tender concerns the acquisition of non-cataloged medicines, specifically Group A, which includes insulins and other related pharmaceutical products, for the first quarter of the 2025 programming year. The procurement process is managed under the Pharmacy and Therapeutics Committee Minutes 002 – 2025. The contracting entity responsible for this tender is the CENTRO CLINICO QUIRURGICO AMBULATORIO HOSPITAL DEL DIA "MARIA ROSA PARRA ARREAGA" (CCQA-HD SAMBORONDON). The procurement method specified is Electronic Reverse Auction (Subasta Inversa Electrónica), a process designed to achieve competitive pricing through an online bidding system. A specific item required under this tender is Ondansetron, a parenteral liquid formulation with a concentration of 2 mg/mL, supplied in boxes of 4 mL ampoules. The quantity requested for Ondansetron is 3000 units, with an estimated value of USD 527,838.00. This tender is crucial for ensuring the availability of essential medications, particularly those not typically found in standard hospital catalogs, to meet patient needs during the specified period. The focus on Group A medications, including insulins, highlights the critical nature of these supplies for ongoing medical treatments and patient care within the Samborondón region.

This is a supplies contract in the governance and public administration sector. Located in Ecuador, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of USD 527,838.

Published through SERCOP Ecuador, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.